Monitor future clinical and commercial strategy updates for signs of accelerated development timelines or partnership activity, as Gilmer's expertise may influence Armata's path to market for its phage-based pipeline. No immediate financial or operational changes are expected from this appointment.
ARMP drugs
ARMP drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 27 $11.00entry
- T+1 · 7mo ago −11.27%α −10.79% · $9.76
- T+5 · 7mo ago −10.45%α −10.85% · $9.85
- T+20 · 6mo ago −25.73%α −30.68% · $8.17
- T+60 · 4mo ago −52.36%α −57.14% · $5.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Armata Pharmaceuticals appointed Dr. Daniel Gilmer, a biopharmaceutical commercial executive with experience at Pfizer and McKinsey, to its Board of Directors. The move adds expertise in commercialization of anti-infectives, including leadership in the U.S. launch of PAXLOVID, to support Armata's development of bacteriophage therapeutics.
Key Facts
- Dr. Daniel Gilmer, Ph.D., appointed to Board of Directors effective April 24, 2026
- Gilmer previously served as Senior Director, Commercial Quality U.S. Team Lead at Pfizer since February 2025
- He led the U.S. launch of PAXLOVID and has experience in commercial strategy, patient access, and antimicrobial resistance
- Gilmer is an equal co-inventor on the patent for Exebacase, a first-in-class bacteriophage lysin
- He will receive an option award to purchase 51,280 shares of common stock, vesting over three years
- No other arrangements or understandings exist with Gilmer beyond standard director compensation
Financial Impact
Minimal immediate financial impact. Director compensation includes $40,000 annual cash retainer and expected option award for 51,280 shares.
Risk Factors
- Integration of new board member may lead to strategic shifts
- No replacement named for any departing executive, indicating potential governance continuity
- Biotech clinical-stage companies face high execution risk in drug development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-048997 |
| Document: tm2612716d1_ex99-1.htm | 0001104659-26-048997 |
| Document: 0001104659-26-048997-index-headers.html | 0001104659-26-048997 |
| Document: 0001104659-26-048997-index.html | 0001104659-26-048997 |
| Document: 0001104659-26-048997.txt | 0001104659-26-048997 |
Track record
6 reports on ARMP
1 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +43.90% at T+60 after the May 13, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $3.87 Now $2.99 −22.74% settles Dec 14
- Sep 23, 20267w ago 8-K Bullish 5/10 Entry $3.64 to $3.06 Now $2.99 −17.86% ▼ −15.93% −16.62% vs SPY
- Sep 14, 20269w ago 8-K Bullish 7/10 Entry $5.55 to $3.63 Now $2.99 −46.13% ▼ −34.59% −36.86% vs SPY
- Jul 20, 202617w ago 8-K Bullish 5/10 Entry $5.06 to $4.48 Now $2.99 −40.91% ▼ −11.46% −15.58% vs SPY
- May 13, 202626w ago 8-K Bearish 6/10 Entry $8.20 to $7.58 Now $2.99 +63.54% ▲ +7.56% +6.70% vs SPY
- Apr 27, 202629w ago 8-K Neutral 3/10 Viewing Entry $11.00 to $8.17 Now $2.99 −72.82% ▼ −25.73% −30.68% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers